Anti-RANKL Inhibits Thymic Function and Causes DRONJ in Mice.

ABSTRACT:

Background

Denosumab, a human monoclonal antibody against receptor activator of nuclear factor-kappa B ligand (RANKL), is a novel bone antiresorptive agent used in patients with osteoporosis or metastatic bone cancer. Denosumab-related osteonecrosis of the jaw (DRONJ) has been recently reported in patients using denosumab. However, the mechanisms of DRONJ are not fully understood. Appropriate pathogenic mechanisms of DRONJ have yet to be established. Therefore, we investigated the pathogenesis of DRONJ in mice.

Methods

Anti-mouse RANKL monoclonal antibody and melphalan were performed to create a mouse model of DRONJ-like lesions in female C57BL/6J mice. We examined the development of DRONJ-like lesions and immune function.

Results

We showed that administration of anti

SUBMITTER: Nakamura Y 

PROVIDER: S-EPMC9033356 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature